Evaluating a Pediatric Asthma Management Education Program for Physicians

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00399984
Recruitment Status : Completed
First Posted : November 15, 2006
Last Update Posted : June 13, 2013
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
Inhaled corticosteroids taken on a daily basis have been proven to be the most effective treatment for children with persistent asthma. However, many pediatricians still do not prescribe daily corticosteroids to their asthmatic patients; this can lead to poor health outcomes among asthmatic children. This study will evaluate an interactive medical education program that focuses on improving pediatricians' asthma management skills and on encouraging increased corticosteroid use among their patients with asthma.

Condition or disease Intervention/treatment Phase
Asthma Education, Medical Behavioral: Asthma Education Program Not Applicable

Detailed Description:

Asthma is a common childhood disease that affects over 9 million children in the United States. In 1997, the National Heart, Lung, and Blood Institute (NHLBI) published a set of guidelines aimed at improving the quality of patient care for individuals with asthma. According to the guidelines, a daily dose of inhaled corticosteroids is considered the most effective treatment for the long-term control of asthma. Despite this recommendation, many pediatricians are not prescribing daily corticosteroids to asthmatic children who may benefit from this treatment.

Continuing medical education (CME) is viewed as the primary method of keeping health care providers informed of new research knowledge and the latest medical trends. While traditional CME programs have not been successful in changing physician behavior, an interactive program that offers skills development for implementing changes in the care and treatment of asthmatic patients may prove effective. The purpose of this study is to develop, implement, and evaluate an interactive asthma education program targeted towards pediatricians. Specifically, the study will determine the program's effectiveness at developing asthma management skills in pediatricians, including corticosteroid prescribing practices, and improving asthma-related outcomes among their pediatric patients.

In this 5-year study, pediatricians will be randomly assigned to either an asthma education intervention group or a control group. The intervention group will attend the enhanced asthma education seminar, and the control group will attend a traditional lecture about asthma. In Years 1 and 2, the intervention group will participate in a 2-hour focus group to discuss barriers to adopting the NHLBI asthma guidelines for daily corticosteroid therapy. A brief survey on this same topic will also be completed. During Year 2, physicians in the intervention group will attend at least 5 hours of educational seminars designed to improve adherence to the recommended guidelines. In Years 2 through 5, all physicians will complete yearly questionnaires to assess barriers to corticosteroid prescription methods. Parents of asthmatic patients treated by the pediatricians will take part in a 20-minute telephone survey each year, and study researchers will review the medical records of each child.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Official Title: Enhancing Pediatric Asthma Management
Study Start Date : April 2004
Actual Primary Completion Date : June 2009
Actual Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: 1 Behavioral: Asthma Education Program
interactive seminars regarding daily inhaled corticosteroids

No Intervention: 2

Primary Outcome Measures :
  1. Changes in physician knowledge, attitudes, and self-reported behavior [ Time Frame: 1-3 years ]
  2. Changes in patient asthma outcomes (both measured on a yearly basis) [ Time Frame: 1-3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Pediatricians must meet all of the following criteria:

    1. Graduate of a pediatric residency program in the United States
    2. In active medical practice for at least 4 half-day sessions, with 40% clinical effort in general pediatrics
    3. At least 54 children with asthma in their patient population
  • Parents of pediatric asthma patients must meet all of the following criteria:

    1. Parent or guardian of a pediatric patient that meets patient eligibility criteria
    2. Able to identify that the participating physician is the child's primary care pediatrician
    3. Provides most asthma management or is the adult who normally takes the child to the doctor
  • Pediatric patients must meet all of the following criteria:

    1. Older than 4 years of age (to decrease the likelihood that the child has bronchiolitis)
    2. Younger than 16 years of age (to ensure that during all 3 years of the evaluation part of the study, the child will be younger than 20 years of age)
    3. Diagnosis of asthma made by a physician using commonly accepted clinical criteria
    4. No other chronic disorders that have pulmonary complications (e.g., sickle cell disease, tuberculosis, acquired immune deficiency syndrome [AIDS], cystic fibrosis)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00399984

United States, California
University of California, San Francisco
San Francisco, California, United States, 94118
Sponsors and Collaborators
University of California, San Francisco
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Michael D. Cabana, MD, MPH University of California, San Francisco

Responsible Party: University of California, San Francisco Identifier: NCT00399984     History of Changes
Other Study ID Numbers: 437
R01HL070771 ( U.S. NIH Grant/Contract )
First Posted: November 15, 2006    Key Record Dates
Last Update Posted: June 13, 2013
Last Verified: June 2013

Keywords provided by University of California, San Francisco:
Continuing Medical Education

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases